Cargando…
P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431134/ http://dx.doi.org/10.1097/01.HS9.0000971364.86087.32 |
| _version_ | 1785091128755748864 |
|---|---|
| author | Minson, Adrian Verner, Emma Giri, Pratyush Min Wong, Shu Ratnasingam, Sumita Butler, Jason Janowski, Wojciech Ku, Matthew Cheah, Chan Hertzberg, Mark Herbert, Kirsten Hamad, Nada Yannakou, Costas Neeson, Paul Saghebi, Javad Blombery, Piers Robertson, Molly Shong Lau, Lei Xie, Jing Seymour, John Dickinson, Michael |
| author_facet | Minson, Adrian Verner, Emma Giri, Pratyush Min Wong, Shu Ratnasingam, Sumita Butler, Jason Janowski, Wojciech Ku, Matthew Cheah, Chan Hertzberg, Mark Herbert, Kirsten Hamad, Nada Yannakou, Costas Neeson, Paul Saghebi, Javad Blombery, Piers Robertson, Molly Shong Lau, Lei Xie, Jing Seymour, John Dickinson, Michael |
| author_sort | Minson, Adrian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431134 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104311342023-08-17 P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY Minson, Adrian Verner, Emma Giri, Pratyush Min Wong, Shu Ratnasingam, Sumita Butler, Jason Janowski, Wojciech Ku, Matthew Cheah, Chan Hertzberg, Mark Herbert, Kirsten Hamad, Nada Yannakou, Costas Neeson, Paul Saghebi, Javad Blombery, Piers Robertson, Molly Shong Lau, Lei Xie, Jing Seymour, John Dickinson, Michael Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431134/ http://dx.doi.org/10.1097/01.HS9.0000971364.86087.32 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Minson, Adrian Verner, Emma Giri, Pratyush Min Wong, Shu Ratnasingam, Sumita Butler, Jason Janowski, Wojciech Ku, Matthew Cheah, Chan Hertzberg, Mark Herbert, Kirsten Hamad, Nada Yannakou, Costas Neeson, Paul Saghebi, Javad Blombery, Piers Robertson, Molly Shong Lau, Lei Xie, Jing Seymour, John Dickinson, Michael P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY |
| title | P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY |
| title_full | P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY |
| title_fullStr | P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY |
| title_full_unstemmed | P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY |
| title_short | P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY |
| title_sort | p1117: glofitamab plus r-chop or polatuzumab vedotin-r-chp is deliverable and yields high overall response in patients <=65 years of age with high-risk dlbcl or hgbl: interim analysis of the coalition study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431134/ http://dx.doi.org/10.1097/01.HS9.0000971364.86087.32 |
| work_keys_str_mv | AT minsonadrian p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT verneremma p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT giripratyush p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT minwongshu p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT ratnasingamsumita p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT butlerjason p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT janowskiwojciech p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT kumatthew p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT cheahchan p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT hertzbergmark p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT herbertkirsten p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT hamadnada p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT yannakoucostas p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT neesonpaul p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT saghebijavad p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT blomberypiers p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT robertsonmolly p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT shonglaulei p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT xiejing p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT seymourjohn p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy AT dickinsonmichael p1117glofitamabplusrchoporpolatuzumabvedotinrchpisdeliverableandyieldshighoverallresponseinpatients65yearsofagewithhighriskdlbclorhgblinterimanalysisofthecoalitionstudy |